Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).

Inclusion Criteria: * Diagnosis of DMD confirmed by genetic report * Age 8 years or older. * Stable glucocorticoid and/or other medication regimen for at least 3 months before enrollment and throughout study participation. Exclusion Criteria: * Unstable medical conditions or significant concomitant illness. * Secondary condition affecting muscle function or metabolism (e.g., myasthenia gravis, endocrine disorders, mitochondrial disease). * Participation in another investigational clinical trial within the previous 3 months.